Financial & Business News

LAS VEGAS , Sept. 5, 2025 /PRNewswire/ -- Southwest Gas Holdings, Inc. (NYSE: SWX) ("Southwest Gas Holdings" or the "Company") today announced the closing of the previously announced registered public offering of Centuri Holdings, Inc. (NYSE: CTRI) ("Centuri") common stock (the "Offering").

- Genevieve Baer and Ezra Laniado resign from the Board of Directors - SAN DIEGO, CA, Sept. 05, 2025 (GLOBE NEWSWIRE) -- RYVYL Inc. (NASDAQ: RVYL) ("RYVYL” or the "Company") has appointed current CFO George Oliva and Gene Jones to its Board of Directors.

BOSTON and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00 am ET on September 8, 2025, to report topline results for the Phase 2a trial of RAP-219 in patients with drug-resistant focal onset seizures.

WALTHAM, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 31,900 shares of common stock of Spyre to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on September 2, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

SAXONBURG, Pa., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in photonics, announced today its membership in the Diode Technology Working Group within the STARFIRE Hub, a collaborative initiative led by Lawrence Livermore National Laboratory (LLNL) to accelerate the development of inertial fusion energy (IFE).

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 2, 2025 (the “Grant Date”), ORIC granted a total of 292,500 non-qualified stock options and 79,000 restricted stock units to one new non-executive officer employee who began their employment with ORIC in August 2025.

Certificate of Amendment Changes Name to FG Nexus Inc., Increases Authorized Shares, Triggers Conversion of Automatic Exercise Pre-Funded Warrants to Common Stock and Expands Outstanding Share Count to Over 35 million

A Tesla shareholder proposal for the electric vehicle maker to invest in Elon Musk's startup xAI will be voted on in November. Retail investor Alexandra Merz, known online as TeslaBoomerMama, joins “Bloomberg Tech” to discuss why she thinks the investment would be a “fantastic opportunity.

NEW YORK, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on September 1, 2025 the Company granted inducement awards to purchase up to 167,400 shares of common stock to 11 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 47,040 shares of the Company's common stock to six new employees (the “Inducement Grants”) on September 3, 2025 (the “Grant Date”). The Indu.